Market Overview

Biotech Stocks Falling Broadly, Here's Why And How Much

Share:
Biotech Stocks Falling Broadly, Here's Why And How Much
Related BIIB
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One
Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2016 Update (Seeking Alpha)
Related SNSS
Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe
Sunesis Pharmaceuticals Announces Presentation of Results Phase 1 Trial of Vosaroxin + Azacitidine at #ASH2015
Boxer Capital, LLC Buys AveXis, BeiGene, Alnylam Pharmaceuticals, Sells Biomarin ... (GuruFocus)

Biotech stocks are plummeting broadly on Friday trading, after Biogen Inc (NASDAQ: BIIB) reported better-than-expected earnings for the second quarter, but missed analysts estimates in the revenue front before the market opened.

The Cambridge, Massachusetts-based company reported earnings of $4.22 per share on revenue of $2.592 billion, while the Street has expecting consensus earnings of $4.10 on sales of $2.711 billion. Moreover, management trimmed its revenue and earnings outlook substantially, reflecting weakening sales of the company’s key multiple-sclerosis drug.

Related Link: RBC's Michael Yee Still Sees Value in Biogen's Long-Term Pipeline

The disappointing results are actually impacting on the most important U.S. stock indexes (although other factors like the underperformance of materials and energy stocks are also gravitating), but mostly on biotech and pharmaceutical stocks. So, without further a due, let’s take a look at some of the biggest losers of the day.

  • Micro-cap Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) fell the most on Friday. However, the 72.6 percent tumble was triggered not only by Biogen’s results, but also by the announcement that the company will be investigated for “issuing materially misleading information to the investing public.”
  • Biogen was the second-largest loser, down roughly 22 percent
  • Small-cap Esperion Therapeutics Inc (NASDAQ: ESPR) dropped more than 20 percent during Friday trading, to $76.00
  • Vital Therapies Inc (NASDAQ: VTL) lost almost 19 percent during the trading day, and continues to fall in after-hours.
  • Another micro-cap, Juniper Pharmaceuticals Inc (NASDAQ: JNP), sunk 17.45 percent

Other relevant movers include:

  • Puma Biotechnology Inc (NYSE: PBYI), down 9.58 percent
  • MannKind Corporation (NASDAQ: MNKD), which plunged 8.12 percent
  • Seres Therapeutics Inc (NASDAQ: MCRB), which descended 7.34 percent
  • Aduro BioTech Inc (NASDAQ: ADRO), down 7.21 percent

Posted-In: VetrBiotech Health Care Movers General

 

Related Articles (BIIB + ADRO)

View Comments and Join the Discussion!